Common Side Effects of Adagrasib

Common Side Effects of Adagrasib

In clinical trials, the most common side effects of Adagrasib (incidence >20%) primarily include gastrointestinal reactions and systemic symptoms. Specifically, diarrhea, nausea, and vomiting occur at higher rates, and some patients may experience dehydration or electrolyte imbalances; fatigue and decreased appetite are also common. In terms of laboratory abnormalities, anemia, elevated serum creatinine, elevated liver enzymes (ALT and AST), and hyponatremia are frequently observed. Additionally, peripheral edema (particularly swelling of the ankles and feet) and dizziness are common adverse reactions. Most side effects are grade 1 or 2 and can be managed with supportive care or temporary dose interruption; severe events may require dose reduction or discontinuation.

Drug Interactions and Contraindications of Adagrasib

Adagrasib is primarily metabolized by the CYP3A enzyme system. Therefore, when co-administered with other drugs that are also metabolized by the same enzyme and have a narrow therapeutic index, it may significantly alter their plasma concentrations, leading to serious adverse reactions. Based on this, Adagrasib is strictly contraindicated for concurrent use with the following drugs: alfuzosin, amiodarone, cisapride, pimozide, quinidine, ergotamine, dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, sirolimus, midazolam, triazolam, ticagrelor, and tacrolimus. If a patient is currently using any of the above medications, they should consult their physician to switch to an alternative drug or adjust the treatment regimen before starting Adagrasib. Caution is also required when using strong or moderate CYP3A inducers or inhibitors, and dose adjustment may be necessary.

Safety Monitoring and Ongoing Evaluation

To ensure the safe and effective use of Adagrasib in real-world settings, the European Medicines Agency requires the sponsor to continuously collect and report all suspected adverse reactions. Healthcare professionals should proactively report any serious or unexpected side effects to the national pharmacovigilance system. The product label already includes detailed management recommendations for different side effects, such as timely fluid replacement and use of antidiarrheals for diarrhea, and monitoring liver function with consideration of dose reduction for elevated liver enzymes. Furthermore, as Adagrasib is a conditional approval drug, its benefit-risk balance will be reassessed annually, and new safety information will be promptly updated in the product label to maximize patient safety.